



UnitedHealthcare Pharmacy - Nevada  
Clinical Pharmacy Programs

Program	Prior Authorization/Notification
Medication	Dificid (fidaxomicin)
Approval Date	12/2019, 12/2020
Effective Date	1/1/2021

**1. Background:**

Dificid is indicated in both adults and pediatrics (6 months and older) for the treatment of *Clostridium difficile* (also called *Clostridioides difficile*) associated diarrhea (CDAD). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Dificid and other antibacterial drugs, Dificid should be used only to treat infections that are proven or strongly suspected to be caused by *Clostridium difficile*.

**2. Coverage Criteria:**

<p><b>A. <u>Authorization Criteria</u></b></p> <p>1. Diagnosis of <i>Clostridium difficile</i>-associated diarrhea (CDAD)</p> <p style="text-align: center;"><b>-AND-</b></p> <p>2. <b>One</b> of the following:</p> <p>a. History of failure, contraindication, or intolerance to Firvanq (vancomycin) oral solution</p> <p style="text-align: center;"><b>-OR-</b></p> <p>b. History of failure, contraindication, or intolerance to vancomycin (Vancocin) oral capsules if the prescriber provides a reason or special circumstance the patient cannot use Firvanq</p> <p style="text-align: center;"><b>-OR-</b></p> <p>c. For continuation of prior Dificid therapy</p> <p><b>Authorization will be issued for 10 days.</b></p>
--

**3. Additional Clinical Rules:**

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.

**4. References:**

1. Dificid Prescribing Information. Merck & Co., Inc. April 2020.
2. Vancocin [package insert]. Baudette, MN: ANI Pharmaceuticals, Inc.; August 2020.
3. Firvanq [package insert]. Wilmington, MA: CutisPharma,; January 2018.
4. McDonald, et al. Clinical Practice Guidelines for Clostridium difficile Infections in Adults and Children: 2017 Update by Infectious Disease Society of America (IDSA) and Society of Healthcare Epidemiology of America (SHEA), Clin Infect Dis. 2018 Mar 19; 66(7):e1-48
5. Kelly C. Clostridioides (formerly Clostridium) difficile infection in adults: Treatment and prevention. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on November 11, 2020.)

Program	Dificid (fidaxomicin) Notification
<b>Change Control</b>	
Date	Change
11/2019	New Program
11/2020	Annual review. No changes to clinical criteria.